At present a clinical trial is ongoing to test the potential of the antibodies-based inhibition of Sema4D as a novel therapeutic strategy for MS, and the phase I has been successfully completed (LaGanke et al., 2017). Here, SEMA4D is linked to myeloid sarcoma.